NTRA News and Press, Natera Inc. From 01/09/24

Shares of Natera, Inc. (NASDAQ: NTRA) traded at a new 52-week high today and are currently trading at $37.53. So far today, approximately 1.19M shares have been exchanged, as compared to an average 30-day volume of 1.17M shares. Natera, Inc., a diagnostics company, develops and commercializes...

2024-01-09 07:23:52 ET More on Natera Natera: Squeezing The Last Drop From NIPT Growth Engine Natera, Inc. (NTRA) Q3 2023 Earnings Call Transcript Natera, Inc. 2023 Q3 - Results - Earnings Call Presentation Natera wins court order barring NeoGenomics from sel...

2023 revenues are expected to be approximately $20 million above top end of guidance Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expec...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 9, 2024 at 3:45 p.m. PT (6:45 p.m. ET). Members of Natera’s management will deliver a...

2023-12-28 14:52:16 ET More on NeoGenomics NeoGenomics, Inc. 2023 Q3 - Results - Earnings Call Presentation NeoGenomics, Inc (NEO) Q3 2023 Earnings Call Transcript NeoGenomics: Short-Term Upsides Possible, Long-Term Not Supported By Economic Value Natera wins...

2023-12-28 06:48:40 ET More on Natera Natera: Squeezing The Last Drop From NIPT Growth Engine Natera, Inc. (NTRA) Q3 2023 Earnings Call Transcript Natera, Inc. 2023 Q3 - Results - Earnings Call Presentation Merck to use Natera's database for oncology drug res...

2023-12-28 05:23:01 ET Summary CareDx specializes in solutions for transplant patients, but faces challenges, including legal setbacks and regulatory hurdles. The company won Medicare coverage for its HeartCare Multimodality Service and raised its revenue guidance for 2023. Ho...

Order enjoins NeoGenomics from making, using, selling or promoting its RaDaR molecular residual disease (MRD) assay in the United States with limited exceptions Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for...